<DOC>
	<DOCNO>NCT03032016</DOCNO>
	<brief_summary>Following licence new drug , Defitelio® , indicate treatment severe Veno-Occlusive Disease liver ( sVOD ) , rare serious complication haematopoietic stem cell transplantation ( HSCT ) , pharmaceutical company manufacture Defitelio® ( Gentium , Jazz Pharmaceuticals Company ) - specific obligation ( SOB ) - require PRAC set disease registry collect safety outcome data , ass pattern utilization Defitelio® post-approval setting . This registry Post Authorization Safety Study ( PASS ) , coordinate European Society Blood Marrow Transplantation ( EBMT ) . Following appropriate consent , data patient undergo haematopoietic stem cell transplantation routinely collect local centre EBMT database . For study , sit ask collect additional anonymised clinical data patient develop complication treat Defitelio® reason sVOD . The study simply require collection data already record patient chart , routinely collect . The study DOES NOT involve decision treatment , clinical decision , merely collection data patient develop complication , whether receive treatment patient treat Defitelio® reason .</brief_summary>
	<brief_title>European VOD Registry</brief_title>
	<detailed_description>Defitelio® grant Marketing Authorisation Europe exceptional circumstance . Defitelio® indicate treatment severe hepatic Veno-Occlusive Disease ( sVOD ) also know sinusoidal obstruction syndrome ( SOS ) haematopoietic stem-cell transplantation ( HSCT ) therapy . It indicate adults adolescent , child infant 1 month age . As specific obligation ( SOB ) , Gentium require set disease registry collect safety outcome data , ass pattern utilization Defitelio® post-approval setting . This multi-centre , multinational prospective observational disease registry patient severe hepatic VOD follow HSCT , record patient treat Defitelio® supportive care . Gentium required ensure information regard potential identify risk report recent version Risk Management Plan collect . Hepatic VOD one common life-threatening regimen-related toxicity constitute barrier successful allogeneic autologous HSCT . VOD characterise rapid weight gain , painful hepatomegaly , hyperbilirubinemia/jaundice , ascites/fluid retention , without identifiable cause liver disease ( Richardson , 2012 ) . In recent survey 135 study perform 1997 October 2007 , overall mean incidence VOD report 13.7 % low rate 9.6 % Baltimore criterion apply ( Coppell , 2010 ) . The severe form disease , usually associate pulmonary dysfunction and/or renal dysfunction ( ie , multi-organ failure , MOF ) , without encephalopathy , mortality rate 80 % 100 day HSCT , report occur 40 % -60 % VOD patient , approximately 3-5 % transplanted patient . Given low incidence sVOD vary size bone marrow transplant centre EU , order collect meaningful clinical data , registry conduct European transplant centre overall number transplant least 100 per year . The main objective registry assess incidence rate specific SAEs interest ( include fatality ) patient severe hepatic VOD treat Defitelio® compare rate occur similar population treat Defitelio® . Secondary objective : - To describe population treat Defibrotide control ( age , gender , ethnicity , patient pre-existing liver severe renal insufficiency; patient intrinsic lung disease ) - To determine incidence rate multiorgan failure ( MOF ) Graft versus host disease ( GvHD ) adult paediatric patient receive Defibrotide control - To determine survival Day+100 post-HSCT , overall mortality mortality due VOD patient treat Defibrotide control - To determine rate VOD/MOF resolution time treatment initiation patient treat Defibrotide control .</detailed_description>
	<mesh_term>Hepatic Veno-Occlusive Disease</mesh_term>
	<mesh_term>Defibrotide</mesh_term>
	<criteria>Patients undergo hematopoietic stem cell transplantation diagnose severe hepatic VOD , agree participate study ( Main population ) . Patients treat defibrotide another condition severe hepatic VOD ( Secondary population ) scope hematopoietic stem cell transplantation . There specific exclusion criterion ; however contraindication , special warning precaution use detailed SPC consider treat physician .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>VOD</keyword>
	<keyword>Defibrotide</keyword>
	<keyword>Defitelio</keyword>
	<keyword>Registry</keyword>
	<keyword>SOS</keyword>
</DOC>